As Africa confronts a dramatic rise in cancer cases, a silent threat is compromising treatment for thousands of patients: substandard and falsified anticancer drugs. A groundbreaking study has found that these ineffective or toxic medicines are prevalent in hospitals and pharmacies across Cameroon, Ethiopia, Kenya, and Malawi, with faulty products detected in all four countries.
The research, a collaboration between a U.S.-based cancer researcher Marya Lieberman and a Professor Ayenew Ashenef at Addis Ababa University, tested 251 samples of seven vital anticancer drugs. The findings are alarming: 17% of the unique drug batches (32 out of 191) did not contain the correct amount of the active pharmaceutical ingredient.
“This is a careful balance between killing the cancer and killing the patient,” explained the lead researcher. “If the dose is too large, toxic side effects can harm the patient. If it’s too small, the cancer may continue to grow, and the patient may lose their precious window for treatment.”
A Continent at a Cancer Crossroads
The study lands as Africa faces a burgeoning cancer epidemic. A decade ago, countries like Ethiopia and Kenya provided cancer care to only a few thousand patients annually. Today, that number has exploded to over 75,000 per year in each country, mirroring a continental trend where over 800,000 people are diagnosed with cancer each year.
This increased demand, however, has strained regulatory systems. Medicine agencies in many African nations lack the capacity to monitor drug quality effectively. This creates a market vulnerable to substandard products, a danger magnified by the high cost of genuine anticancer drugs and their inherently toxic nature.
Sophisticated Testing Reveals an Invisible Threat
The research team collected drugs covertly and overtly from 12 hospitals and 25 private pharmacies, covering both public and private healthcare systems. To assess quality, they used High-Performance Liquid Chromatography (HPLC), the scientific “gold standard” for quantifying active ingredients.
A product is considered substandard if its active ingredient falls outside the 90%-110% range of the amount stated on the label. The study found numerous vials that fell far short of this requirement.
Perhaps the most disturbing finding was that visual inspection—the primary method used in most African countries to spot fakes—was virtually useless. Only three of the 32 failed products showed any visible irregularities.
“Products that failed the gold-standard test could not be distinguished visually from products that passed,” the researcher noted. “This means healthcare providers and patients have no way of knowing if the medicine being administered is real or not.”
A Call for Global Action and Local Strengthening
The situation uncovered in this study is likely representative of many other low-income countries. The researchers have shared their findings with the national regulators in the four countries involved and are working to build capacity for better post-market surveillance.
The study calls for the global research community to focus more attention on anticancer drug quality, similar to the concerted effort that improved the quality of antimalarial drugs in the 2000s.
“For oncology practitioners and health systems in sub-Saharan Africa, the first step is awareness of this possible presence of substandard products,” the researchers concluded. “We must now work collectively to strengthen regulatory systems to provide better surveillance and protect patients who are fighting for their lives.”
